(redirected from Nicotinic receptor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: receiver
Mentioned in ?
References in periodicals archive ?
These neuronal nicotinic receptor (NNR) assets were reportedly under development by Targacept prior to its 2015 merger with Catalyst.
The finding may also have benefits in creating medications for certain types of epilepsy, mental illness, and dementia such as Alzheimer's, which are also associated with the nicotinic receptor, the researchers said.
In the hippocampus and frontal cortex, the level of CHRNA7 and the alpha-7 nicotinic receptor is almost 10-fold greater during fetal development than during adult life.
Varenicline: An a402 nicotinic receptor partial agonist for smoking cessation.
ABT-126 potentiates the action of the alpha-7 nicotinic receptor, which is expressed both pre- and postsynaptically.
Washington, November 9 ( ANI ): Inactivation of a specific sub-class of nicotinic receptors may be an effective strategy to help smokers quit without feeling anxious, US researchers suggest.
The second step in determining the mode of chemical agents which induce contractions of isolated GI smooth muscle preparations is usually the verification of the participation of nicotinic receptors located in ganglions of enteric nervous system.
This research, funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, shows that a specific subclass of brain nicotinic receptor is involved in nicotine's ability to reduce food intake in rodents.
The different approaches proposed or tested included intervention with acetylcholine (ACh) precursors, stimulation of ACh release, use of muscarinic or nicotinic receptor agonists and acetylcholinesterase (AChE) or cholinesterase (ChE) inhibition.
Mecamylamine is a broad-spectrum nicotinic receptor antagonist, meaning that it blocks receptors located in the periphery of,, as well as those in, the CNS.
a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), has initiated a Phase I clinical trial of TC-5619, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7.